Published in Proc Natl Acad Sci U S A on November 21, 2000
Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc Natl Acad Sci U S A (2001) 5.83
Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J Virol (2002) 5.21
Viral late domains. J Virol (2002) 4.51
Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc Natl Acad Sci U S A (2000) 4.31
A role for ubiquitin ligase recruitment in retrovirus release. Proc Natl Acad Sci U S A (2000) 4.19
Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. Proc Natl Acad Sci U S A (2002) 4.14
Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci U S A (2006) 3.43
Role of ESCRT-I in retroviral budding. J Virol (2003) 3.36
Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4. J Virol (2003) 3.05
Proteins related to the Nedd4 family of ubiquitin protein ligases interact with the L domain of Rous sarcoma virus and are required for gag budding from cells. Proc Natl Acad Sci U S A (2001) 3.04
Mammalian class E vps proteins recognize ubiquitin and act in the removal of endosomal protein-ubiquitin conjugates. J Cell Biol (2002) 2.94
The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner. J Virol (2002) 2.66
Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction. J Virol (2001) 2.66
Structure and functional interactions of the Tsg101 UEV domain. EMBO J (2002) 2.40
HECT ubiquitin ligases link viral and cellular PPXY motifs to the vacuolar protein-sorting pathway. J Cell Biol (2004) 2.34
Ubiquitin depletion as a key mediator of toxicity by translational inhibitors. Mol Cell Biol (2003) 2.29
Functional involvement of a novel Nedd4-like ubiquitin ligase on retrovirus budding. EMBO Rep (2002) 2.22
The Mason-Pfizer monkey virus PPPY and PSAP motifs both contribute to virus release. J Virol (2003) 2.19
Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production. J Virol (2006) 2.18
The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev (2001) 2.18
Ubiquitin in retrovirus assembly: actor or bystander? Proc Natl Acad Sci U S A (2000) 2.08
Human ESCRT-II complex and its role in human immunodeficiency virus type 1 release. J Virol (2006) 2.06
Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection. J Virol (2005) 2.05
Requirements for budding of paramyxovirus simian virus 5 virus-like particles. J Virol (2002) 2.02
As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity. J Virol (2003) 1.94
Context-dependent effects of L domains and ubiquitination on viral budding. J Virol (2004) 1.92
Evidence for a new viral late-domain core sequence, FPIV, necessary for budding of a paramyxovirus. J Virol (2005) 1.88
Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Negl Trop Dis (2007) 1.86
PPPYVEPTAP motif is the late domain of human T-cell leukemia virus type 1 Gag and mediates its functional interaction with cellular proteins Nedd4 and Tsg101 [corrected]. J Virol (2003) 1.80
Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 overexpression. J Virol (2003) 1.79
Virus budding and the ESCRT pathway. Cell Host Microbe (2013) 1.70
Budding of equine infectious anemia virus is insensitive to proteasome inhibitors. J Virol (2002) 1.67
Budding of PPxY-containing rhabdoviruses is not dependent on host proteins TGS101 and VPS4A. J Virol (2004) 1.64
Equine infectious anemia virus and the ubiquitin-proteasome system. J Virol (2002) 1.63
Late assembly domain function can exhibit context dependence and involves ubiquitin residues implicated in endocytosis. J Virol (2002) 1.61
Functional replacement and positional dependence of homologous and heterologous L domains in equine infectious anemia virus replication. J Virol (2002) 1.60
Late domain-dependent inhibition of equine infectious anemia virus budding. J Virol (2004) 1.57
Ubiquitin-dependent virus particle budding without viral protein ubiquitination. Proc Natl Acad Sci U S A (2007) 1.51
No strings attached: the ESCRT machinery in viral budding and cytokinesis. J Cell Sci (2009) 1.50
Pyrrolidine dithiocarbamate reduces coxsackievirus B3 replication through inhibition of the ubiquitin-proteasome pathway. J Virol (2005) 1.50
Proteasome inhibitors block a late step in lysosomal transport of selected membrane but not soluble proteins. Mol Biol Cell (2001) 1.47
The PPPY motif of human T-cell leukemia virus type 1 Gag protein is required early in the budding process. J Virol (2002) 1.45
Paramyxovirus assembly and budding: building particles that transmit infections. Int J Biochem Cell Biol (2010) 1.44
Mammalian Orc1 protein is selectively released from chromatin and ubiquitinated during the S-to-M transition in the cell division cycle. Mol Cell Biol (2002) 1.44
The interferon-induced gene ISG15 blocks retrovirus release from cells late in the budding process. J Virol (2010) 1.42
Late assembly motifs of human T-cell leukemia virus type 1 and their relative roles in particle release. J Virol (2004) 1.34
Retroviruses have differing requirements for proteasome function in the budding process. J Virol (2003) 1.34
Intracellular trafficking and maturation of herpes simplex virus type 1 gB and virus egress require functional biogenesis of multivesicular bodies. J Virol (2007) 1.33
Ubiquitin charging of human class III ubiquitin-conjugating enzymes triggers their nuclear import. J Cell Biol (2004) 1.33
Ubiquitin-regulated nuclear-cytoplasmic trafficking of the Nipah virus matrix protein is important for viral budding. PLoS Pathog (2010) 1.32
Human immunodeficiency virus type 1 Gag contains a dileucine-like motif that regulates association with multivesicular bodies. J Virol (2004) 1.32
Nonstructural protein 3 of bluetongue virus assists virus release by recruiting ESCRT-I protein Tsg101. J Virol (2006) 1.30
Role of Nedd4 and ubiquitination of Rous sarcoma virus Gag in budding of virus-like particles from cells. J Virol (2004) 1.27
Equine infectious anemia virus utilizes host vesicular protein sorting machinery during particle release. J Virol (2003) 1.27
Antiviral activity of innate immune protein ISG15. J Innate Immun (2009) 1.25
Functional roles of equine infectious anemia virus Gag p9 in viral budding and infection. J Virol (2001) 1.24
Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. J Virol (2001) 1.22
Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes. J Virol (2009) 1.22
Autographa californica multiple nucleopolyhedrovirus exon0 (orf141), which encodes a RING finger protein, is required for efficient production of budded virus. J Virol (2004) 1.20
Proteasome inhibition reduces coxsackievirus B3 replication in murine cardiomyocytes. Am J Pathol (2003) 1.19
Both the PPPY and PTAP motifs are involved in human T-cell leukemia virus type 1 particle release. J Virol (2004) 1.17
The functionally exchangeable L domains in RSV and HIV-1 Gag direct particle release through pathways linked by Tsg101. Traffic (2005) 1.16
Lysines close to the Rous sarcoma virus late domain critical for budding. J Virol (2004) 1.16
Analysis of human immunodeficiency virus type 1 Gag ubiquitination. J Virol (2005) 1.15
The trans-Golgi network-associated human ubiquitin-protein ligase POSH is essential for HIV type 1 production. Proc Natl Acad Sci U S A (2005) 1.14
Functional replacement of a retroviral late domain by ubiquitin fusion. Traffic (2008) 1.14
Endophilins interact with Moloney murine leukemia virus Gag and modulate virion production. J Biol (2003) 1.14
Cumulative mutations of ubiquitin acceptor sites in human immunodeficiency virus type 1 gag cause a late budding defect. J Virol (2006) 1.11
Functional interchangeability of late domains, late domain cofactors and ubiquitin in viral budding. PLoS Pathog (2010) 1.10
Ubiquitination is required for effective replication of coxsackievirus B3. PLoS One (2008) 1.09
Importin-beta family members mediate alpharetrovirus gag nuclear entry via interactions with matrix and nucleocapsid. J Virol (2006) 1.09
Analysis of bovine leukemia virus gag membrane targeting and late domain function. J Virol (2002) 1.07
Conserved motifs within Ebola and Marburg virus VP40 proteins are important for stability, localization, and subsequent budding of virus-like particles. J Virol (2009) 1.06
The late-domain-containing protein p6 is the predominant phosphoprotein of human immunodeficiency virus type 1 particles. J Virol (2002) 1.04
A catalytic independent function of the deubiquitinating enzyme USP14 regulates hippocampal synaptic short-term plasticity and vesicle number. J Physiol (2013) 1.04
Mechanism of inhibition of retrovirus release from cells by interferon-induced gene ISG15. J Virol (2011) 1.02
Tyrosine residues direct the ubiquitination and degradation of the NY-1 hantavirus G1 cytoplasmic tail. J Virol (2003) 1.02
Role of ubiquitin and proteasomes in phagosome maturation. Mol Biol Cell (2005) 1.01
ALIX is a Lys63-specific polyubiquitin binding protein that functions in retrovirus budding. Dev Cell (2012) 1.01
GISP binding to TSG101 increases GABA receptor stability by down-regulating ESCRT-mediated lysosomal degradation. J Neurochem (2008) 0.99
Avian sarcoma virus and human immunodeficiency virus, type 1 use different subsets of ESCRT proteins to facilitate the budding process. J Biol Chem (2008) 0.99
Ubiquitin conjugation to Gag is essential for ESCRT-mediated HIV-1 budding. Retrovirology (2013) 0.98
The deubiquitinating enzyme Ubp1 affects sorting of the ATP-binding cassette-transporter Ste6 in the endocytic pathway. Mol Biol Cell (2005) 0.97
Dysregulation of the ubiquitin-proteasome system by curcumin suppresses coxsackievirus B3 replication. J Virol (2007) 0.97
Heterologous late-domain sequences have various abilities to promote budding of human immunodeficiency virus type 1. J Virol (2005) 0.97
The role of WWP1-Gag interaction and Gag ubiquitination in assembly and release of human T-cell leukemia virus type 1. J Virol (2007) 0.96
The Mechanism of Budding of Retroviruses From Cell Membranes. Adv Virol (2009) 0.94
The C-terminal half of TSG101 blocks Rous sarcoma virus budding and sequesters Gag into unique nonendosomal structures. J Virol (2005) 0.92
The late stage of human immunodeficiency virus type 1 assembly is an energy-dependent process. J Virol (2001) 0.91
Specificity of plasma membrane targeting by the rous sarcoma virus gag protein. J Virol (2003) 0.90
Viral takeover of the host ubiquitin system. Front Microbiol (2011) 0.90
Ubiquitin ligase activities of Bombyx mori nucleopolyhedrovirus RING finger proteins. J Virol (2003) 0.89
Hepatitis B virus replication and release are independent of core lysine ubiquitination. J Virol (2009) 0.88
Replication of the rotavirus genome requires an active ubiquitin-proteasome system. J Virol (2011) 0.88
Cargo- and compartment-selective endocytic scaffold proteins. Biochem J (2004) 0.85
Evidence for ubiquitin-regulated nuclear and subnuclear trafficking among Paramyxovirinae matrix proteins. PLoS Pathog (2015) 0.85
Endoplasmic reticulum-associated degradation controls cell surface expression of γ-aminobutyric acid, type B receptors. J Biol Chem (2013) 0.84
The role of ITCH protein in human T-cell leukemia virus type 1 release. J Biol Chem (2011) 0.84
Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol (1998) 14.83
Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A (1991) 10.05
Continuous tissue culture cell lines derived from chemically induced tumors of Japanese quail. Cell (1977) 7.23
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol (1995) 6.87
Fab1p PtdIns(3)P 5-kinase function essential for protein sorting in the multivesicular body. Cell (1998) 6.07
An assembly domain of the Rous sarcoma virus Gag protein required late in budding. J Virol (1994) 5.87
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A (1999) 5.28
Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins. J Virol (1995) 4.92
Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays (2000) 4.38
Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc Natl Acad Sci U S A (2000) 4.31
Suppression of retroviral MA deletions by the amino-terminal membrane-binding domain of p60src. J Virol (1991) 4.25
A role for ubiquitin ligase recruitment in retrovirus release. Proc Natl Acad Sci U S A (2000) 4.19
Equine infectious anemia virus utilizes a YXXL motif within the late assembly domain of the Gag p9 protein. J Virol (1997) 4.08
Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain. J Virol (1996) 3.97
A proline-rich motif within the matrix protein of vesicular stomatitis virus and rabies virus interacts with WW domains of cellular proteins: implications for viral budding. J Virol (1999) 3.92
A proline-rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release. J Virol (1998) 3.69
Mutations altering the moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle. EMBO J (1999) 3.67
Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae. J Biol Chem (1996) 3.54
Incorporation of chimeric gag protein into retroviral particles. J Virol (1990) 3.43
WW domains and retrovirus budding. Nature (1996) 3.10
The differential miscibility of lipids as the basis for the formation of functional membrane rafts. Biochim Biophys Acta (1998) 2.94
The I domain is required for efficient plasma membrane binding of human immunodeficiency virus type 1 Pr55Gag. J Virol (1998) 2.93
Late domain function identified in the vesicular stomatitis virus M protein by use of rhabdovirus-retrovirus chimeras. J Virol (1999) 2.90
A function for monoubiquitination in the internalization of a G protein-coupled receptor. Mol Cell (1998) 2.81
Rapid deubiquitination of nucleosomal histones in human tumor cells caused by proteasome inhibitors and stress response inducers: effects on replication, transcription, translation, and the cellular stress response. Biochemistry (1997) 2.73
Equine infectious anemia virus Gag polyprotein late domain specifically recruits cellular AP-2 adapter protein complexes during virion assembly. J Virol (1998) 2.68
Monoubiquitin carries a novel internalization signal that is appended to activated receptors. EMBO J (2000) 2.54
Ubiquitin-dependent internalization and down-regulation of plasma membrane proteins. FASEB J (1997) 2.45
Necessity of the spacer peptide between CA and NC in the Rous sarcoma virus gag protein. J Virol (1993) 2.40
Metabolism of the polyubiquitin degradation signal: structure, mechanism, and role of isopeptidase T. Biochemistry (1995) 2.31
Fc epsilon RI-mediated recruitment of p53/56lyn to detergent-resistant membrane domains accompanies cellular signaling. Proc Natl Acad Sci U S A (1995) 2.30
Mass determination of rous sarcoma virus virions by scanning transmission electron microscopy. J Virol (1999) 2.15
Ubiquitin in avian leukosis virus particles. Virology (1990) 2.13
The C2 domain of the ubiquitin protein ligase Nedd4 mediates Ca2+-dependent plasma membrane localization. J Biol Chem (1997) 1.85
Regulation of the epithelial Na+ channel by Nedd4 and ubiquitination. Kidney Int (2000) 1.67
Expression of a ubiquitin derivative that conjugates to protein irreversibly produces phenotypes consistent with a ubiquitin deficiency. J Biol Chem (1992) 1.61
Substrate properties of site-specific mutant ubiquitin protein (G76A) reveal unexpected mechanistic features of ubiquitin-activating enzyme (E1). J Biol Chem (1994) 1.54
Particle size determinants in the human immunodeficiency virus type 1 Gag protein. J Virol (1998) 1.48
MDP1, a Saccharomyces cerevisiae gene involved in mitochondrial/cytoplasmic protein distribution, is identical to the ubiquitin-protein ligase gene RSP5. Genetics (1997) 1.41
Membrane targeting properties of a herpesvirus tegument protein-retrovirus Gag chimera. J Virol (2000) 1.36
A Di-leucine signal in the ubiquitin moiety. Possible involvement in ubiquitination-mediated endocytosis. J Biol Chem (2000) 1.35
Identification of retroviral late domains as determinants of particle size. J Virol (1999) 1.25
Active site-directed inhibitors of Rhodococcus 20 S proteasome. Kinetics and mechanism. J Biol Chem (1997) 1.23
Conditions for copackaging rous sarcoma virus and murine leukemia virus Gag proteins during retroviral budding. J Virol (1999) 1.07
Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (1995) 9.79
Form, function, and use of retroviral gag proteins. AIDS (1991) 9.24
Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol (2000) 9.16
Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol (1994) 6.67
Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins. J Virol (1995) 4.92
DNA content, kinetic complexity, and the ploidy question in Candida albicans. Mol Cell Biol (1982) 4.64
Equine infectious anemia virus utilizes a YXXL motif within the late assembly domain of the Gag p9 protein. J Virol (1997) 4.08
Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain. J Virol (1996) 3.97
Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins. J Virol (1993) 3.71
Nedd8 modification of cul-1 activates SCF(beta(TrCP))-dependent ubiquitination of IkappaBalpha. Mol Cell Biol (2000) 3.51
Ubiquitination. Annu Rev Cell Biol (1991) 3.48
Incorporation of chimeric gag protein into retroviral particles. J Virol (1990) 3.43
The short-lived MAT alpha 2 transcriptional regulator is ubiquitinated in vivo. Proc Natl Acad Sci U S A (1991) 3.42
Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant. Mol Cell Biol (1994) 3.27
Characterization of a small (25-kilodalton) derivative of the Rous sarcoma virus Gag protein competent for particle release. J Virol (1993) 3.19
Mutations of the Rous sarcoma virus env gene that affect the transport and subcellular location of the glycoprotein products. J Cell Biol (1984) 3.11
WW domains and retrovirus budding. Nature (1996) 3.10
Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci U S A (1987) 2.97
Late domain function identified in the vesicular stomatitis virus M protein by use of rhabdovirus-retrovirus chimeras. J Virol (1999) 2.90
Ubiquitination of the G1 cyclin Cln2p by a Cdc34p-dependent pathway. EMBO J (1995) 2.82
Genetic analysis of the major homology region of the Rous sarcoma virus Gag protein. J Virol (1995) 2.76
A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proc Natl Acad Sci U S A (2000) 2.69
Repetitive DNA of Candida albicans: nuclear and mitochondrial components. J Bacteriol (1984) 2.52
Necessity of the spacer peptide between CA and NC in the Rous sarcoma virus gag protein. J Virol (1993) 2.40
Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly. J Virol (1991) 2.38
Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly. J Virol (1991) 2.23
Importance of basic residues in the nucleocapsid sequence for retrovirus Gag assembly and complementation rescue. J Virol (1998) 2.18
Proteasome inhibition measurements: clinical application. Clin Chem (2000) 2.04
A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virol (1995) 1.93
Intracellular trafficking of the UL11 tegument protein of herpes simplex virus type 1. J Virol (2001) 1.90
The bacterially expressed yeast CDC34 gene product can undergo autoubiquitination to form a multiubiquitin chain-linked protein. J Biol Chem (1993) 1.86
Circular mitochondrial genome of Candida albicans contains a large inverted duplication. J Bacteriol (1985) 1.84
Evidence for a second function of the MA sequence in the Rous sarcoma virus Gag protein. J Virol (1996) 1.70
Efficiency and selectivity of RNA packaging by Rous sarcoma virus Gag deletion mutants. J Virol (1994) 1.70
Polyubiquitination is required for US11-dependent movement of MHC class I heavy chain from endoplasmic reticulum into cytosol. Mol Biol Cell (2001) 1.69
Genetic determinants of Rous sarcoma virus particle size. J Virol (1998) 1.67
A uniform isopeptide-linked multiubiquitin chain is sufficient to target substrate for degradation in ubiquitin-mediated proteolysis. J Biol Chem (1990) 1.62
Second-site suppressors of Rous sarcoma virus Ca mutations: evidence for interdomain interactions. J Virol (2001) 1.55
Ubiquitin conjugation by the yeast RAD6 and CDC34 gene products. Comparison to their putative rabbit homologs, E2(20K) AND E2(32K). J Biol Chem (1991) 1.55
Particle size determinants in the human immunodeficiency virus type 1 Gag protein. J Virol (1998) 1.48
Recent advances and remaining problems in HIV assembly. AIDS (1998) 1.46
A large region within the Rous sarcoma virus matrix protein is dispensable for budding and infectivity. J Virol (1996) 1.43
Ubiquitin and microtubule-associated protein tau immunoreactivity each define distinct structures with differing distributions and solubility properties in Alzheimer brain. Proc Natl Acad Sci U S A (1988) 1.41
The membrane-binding domain of the Rous sarcoma virus Gag protein. J Virol (1996) 1.39
Membrane targeting properties of a herpesvirus tegument protein-retrovirus Gag chimera. J Virol (2000) 1.36
Myristylation of Rous sarcoma virus Gag protein does not prevent replication in avian cells. J Virol (1990) 1.36
Repositioning basic residues in the M domain of the Rous sarcoma virus gag protein. J Virol (2000) 1.33
Alterations in the transport and processing of Rous sarcoma virus envelope glycoproteins mutated in the signal and anchor regions. J Cell Biochem (1983) 1.31
Identification of retroviral late domains as determinants of particle size. J Virol (1999) 1.25
Functional and physical characterization of the cell cycle ubiquitin-conjugating enzyme CDC34 (UBC3). Identification of a functional determinant within the tail that facilitates CDC34 self-association. J Biol Chem (1994) 1.24
Amino-terminal deletion mutants of the Rous sarcoma virus glycoprotein do not block signal peptide cleavage but can block intracellular transport. J Cell Biol (1986) 1.21
Specific recognition of calmodulin from Dictyostelium discoideum by the ATP, ubiquitin-dependent degradative pathway. J Biol Chem (1985) 1.20
Crystal structure of a class I ubiquitin conjugating enzyme (Ubc7) from Saccharomyces cerevisiae at 2.9 angstroms resolution. Biochemistry (1997) 1.20
Isolation of virus-neutralizing RNAs from a large pool of random sequences. Proc Natl Acad Sci U S A (1995) 1.18
RNA dimerization defect in a Rous sarcoma virus matrix mutant. J Virol (2000) 1.18
Expression of the Rous sarcoma virus env gene from a simian virus 40 late-region replacement vector: effects of upstream initiation codons. J Virol (1987) 1.18
Tertiary structures of class I ubiquitin-conjugating enzymes are highly conserved: crystal structure of yeast Ubc4. Biochemistry (1993) 1.18
Mechanism of activation of cyclic nucleotide phosphodiesterase: requirement of the binding of four Ca2+ to calmodulin for activation. Proc Natl Acad Sci U S A (1981) 1.13
Triggered activity in the heart: cellular mechanisms of early after-depolarizations. Eur Heart J (1991) 1.12
Clinically silent preoperative brain injuries do not worsen with surgery in neonates with congenital heart disease. J Thorac Cardiovasc Surg (2010) 1.10
Characterization of a dominant negative mutant of the cell cycle ubiquitin-conjugating enzyme Cdc34. J Biol Chem (1995) 1.08
Molecular cloning of the Mason-Pfizer monkey virus genome: characterization and cloning of subgenomic fragments. Virology (1985) 1.08
Conditions for copackaging rous sarcoma virus and murine leukemia virus Gag proteins during retroviral budding. J Virol (1999) 1.07
Kinetic studies on the dissociation of adenosine cyclic 3',5'-monophosphate from the regulatory subunit of protein kinase from rabbit skeletal muscle. Biochemistry (1980) 1.01
Antibodies directed against ubiquitin inhibit high affinity [3H]choline uptake in rat cerebral cortical synaptosomes. J Biol Chem (1986) 1.01
Isolation and chemical characterization of Alzheimer's disease paired helical filament cytoskeletons: differentiation from amyloid plaque core protein. J Cell Biol (1988) 1.01
Brain injury patterns in hypoglycemia in neonatal encephalopathy. AJNR Am J Neuroradiol (2013) 0.99
On the mechanism of activation of cyclic mucleotide phosphodiesterase by calmodulin. Ann N Y Acad Sci (1980) 0.98
Kinetics and thermodynamics of the interaction of elongation factor Tu with elongation factor Ts, guanine nucleotides, and aminoacyl-tRNA. J Biol Chem (1985) 0.97
Bacterially synthesized vertebrate calmodulin is a specific substrate for ubiquitination. J Biol Chem (1987) 0.94
The yeast UBC4 ubiquitin conjugating enzyme monoubiquitinates itself in vivo: evidence for an E2-E2 homointeraction. Biochemistry (1995) 0.92
Kinetic studies on the interactions of Escherichia coli K12 elongation factor Tu with GDP and elongation factor Ts. J Biol Chem (1981) 0.90
Specific disulfide cleavage is required for ubiquitin conjugation and degradation of lysozyme. J Biol Chem (1991) 0.88
Transport and processing of the Rous sarcoma virus Gag protein in the endoplasmic reticulum. J Virol (1996) 0.86
The major site of phosphorylation within the Rous sarcoma virus MA protein is not required for replication. J Virol (1998) 0.84
Bovine serum albumin as catalyst. III. Conformational studies. J Am Chem Soc (1975) 0.82
Fluorometric assay for adenosine 3',5'-cyclic monophosphate-dependent protein kinase and phosphoprotein phosphatase activities. Proc Natl Acad Sci U S A (1981) 0.80
Mechanism of enzyme regulation by calmodulin and Ca2+. Curr Top Cell Regul (1985) 0.80
Insertion of capsid proteins from nonenveloped viruses into the retroviral budding pathway. J Virol (2001) 0.77
Automation and validation of micronucleus detection in the 3D EpiDerm™ human reconstructed skin assay and correlation with 2D dose responses. Mutagenesis (2014) 0.77
Prenatal and postnatal inflammation in relation to cortisol levels in preterm infants at 18 months corrected age. J Perinatol (2013) 0.75
Pathological case of the month. Congenital muscular torticollis. Arch Pediatr Adolesc Med (1996) 0.75
Ubiquitin-directed antibodies inhibit neuronal transporters in rat brain synaptosomes. J Neurochem (1987) 0.75
Bacterial expression of the Saccharomyces cerevisiae ubiquitin-conjugating enzyme Ubc7. Protein Expr Purif (1996) 0.75
Bovine serum albumin as a catalyst. II. Characterization of the kinetics. J Am Chem Soc (1975) 0.75
Stopped-flow studies on the n equilibrium f transition in serum albumin. Biophys Chem (1978) 0.75
Esophagoscopy. An analysis of two hundred cases. Med Ann Dist Columbia (1966) 0.75